[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"eating-disorder-binge\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:eating-disorder-binge":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,54,112,136],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":36,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100053868","halo-trial-high-medium-and-low-intensity-psychotherapy-for-binge-eating-disorder-100053868",false,"NCT07698132","HALO-TRIAL: High, Medium And LOw Intensity Psychotherapy for Binge Eating Disorder","HALO","Inclusion Criteria:\n\n* Binge Eating Disorder according to DSM-5 criteria\n* 18-65 years of age\n* Fluent Danish speaker\n\nExclusion Criteria:\n\n* Concurrent psychotherapeutic treatment\n* Use of weight loss medications within the last month (i.e., GLP-1 receptor antagonists)\n* Suicidal ideation or suicidality\n* Psychosis or psychotic disorders\n* Mania or bipolar disorder\n* Drug misuse disorder\n* Alcohol misuse disorder\n* Cluster B personality disorders in the severe range (diagnosed)\n* Dosage of Antidepressants, Antipsychotics and Stimulants must be stable for at least 6 months","ALL","18 Years","65 Years",{"count":20,"type":21},256,"ESTIMATED","INTERVENTIONAL",[24],"NA","The HALO trial is designed as a four-armed, assessor-blinded, fidelity-monitored randomized clinical trial. The goal of this randomized controlled study is to investigate the effectiveness of four different psychotherapy programs and to determine which one is most effective in reducing the number of binge-eating episodes in people with the eating disorder Binge Eating Disorder (BED), by directly comparing three intensities of Cognitive Behavioral Therapy-Enhanced against a manualized treatment as usual.\n\nParticipants will be asked to complete a 21-weeks randomized intervention and participate in follow up assesments.",[27,28,29,30,31,32,33,34,35],"Binge Eating Disorder","Binge Eating Episodes","Binge Eating\u002FLoss of Control Eating","Binge Eating Disorders","Binge Eating","Binge Eating Behaviour","Binge Eating Disorder Associated With Obesity","Eating Disorder Binge","Eating Disorders",[27,35,37,38,39,40],"Cognitive Behavioral Therapy","Psychotherapy","Randomized Controlled Trial","Evidence-based Psychiatry","RECRUITING","2026-07-07",{"date":44,"type":45},"2026-07-13","ACTUAL",{"date":47,"type":45},"2024-06-10",{"date":49,"type":21},"2032-12",{"name":51,"class":52},"Herlev and Gentofte Hospital","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":86,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100609246","precision-subclassification-of-mental-health-in-diabetes-digital-twins-for-precision-mental-health-to-track-subgroups-100609246","NCT07212075","Precision Subclassification of Mental Health in Diabetes: Digital Twins for Precision Mental Health to Track Subgroups","TwinPeaks","Inclusion Criteria:\n\n* 18 to 80 years of age\n* Diagnosis of type 1 diabetes or type 2 diabetes or other specific type of diabetes\n* Diabetes duration ≥ 1 year\n* Sufficient German language skills\n* Informed consent\n\nExclusion Criteria:\n\n* Inability to consent\n* Significant cognitive impairment (e.g. dementia)\n* Severe disorder or condition impacting the person's ability to participate in the study or likely to confound results (e.g. treated cancer, heart disease ≥ NYHA III, schizophrenia\u002Fpsychotic disorder)\n* Terminal illness\n* Being bedridden","80 Years",{"count":63,"type":21},1809,"OBSERVATIONAL","Mental conditions and disorders (e.g. distress, depressive, anxiety, and eating disorders) are more prevalent in people with diabetes (PWD) and associated with reduced quality of life and impaired glycaemic outcomes. Evidence supports a complex network between psychosocial factors and glycaemic control that can be highly variable between persons. It is assumed that subgroups exist that show different trajectories of glycaemia and mental health.\n\nBelonging to a particular subgroup may be linked with a higher risk of developing mental health problems compared to others. This suggests that it is possible to treat individuals in different subgroups in a manner that optimizes their treatment and can improve health outcomes. Accurate characterisation can inform more individualized care. This calls for a more personalised approach considering the idiosyncrasies of different subgroups.\n\nOver 3 years, the investigators have established the basis of a precision mental health approach for diabetes using n-of-1 analyses. By utilizing combined ecological momentary assessment (EMA: repeated daily sampling of psychosocial factors in everyday life) and continuous glucose monitoring (CGM), intensive longitudinal data per person could be collected. This enables the analysis of individual associations between glycaemic parameters and psychosocial variables and identification of individual sources of diabetes distress in each person.\n\nThe objective of the present study is to use of the n-of-1 approach to identify subgroups of PWD who share common characteristics in the associations between glucose and psychosocial variables. The identified subgroups shall be used to develop a digital twin for precision mental health in diabetes. The digital twin serves as representation of a real person, allowing to make simulations and predictions of the course of mental health and glycaemia. These predictions can inform diabetes care and lead to more precise, personalised treatment decisions.\n\nTo achieve this, a longitudinal panel including over 1,400 PWD who continuously complete EMA and questionnaire surveys and measure glucose levels using CGM was developed. Over 1000 clinical interviews to diagnose mental disorders have been conducted to identify major mental health conditions and map mental outcomes. To identify subgroups and develop the digital twin, the sampling will be expanded aiming at a total of 1,809 PWD. Incidence and remission of mental disorders will be determined via repeated interviews.\n\nThe complex networks between clinical, metabolic, and psychosocial data will be analysed using machine learning, leading to new insights with the potential to shape future guidelines. These results will be used by the digital twin to predict courses of glycaemic control and mental health, translating the individual evidence into direct treatment suggestions.",[67,68,69,70,71,72,73,74,75,76,77,78,34,79,80,81,82,83,84,85],"Diabetes (DM)","Diabete Mellitus","Diabete Type 1","Diabete Type 2","Diabetes Distress","Diabetes Complications","Depression - Major Depressive Disorder","Depression Anxiety Disorder","Depression Bipolar","Depression Disorders","Anxiety Disorder (Panic Disorder or GAD)","Anxiety Disorder NOS","Anorexia Nervosa","Bulimia Nervosa","Eating Disorder Not Otherwise Specified","Depressed Mood","Anxiety Symptoms","Disordered Eating Behaviors","Fear of Hypoglycemia",[87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,71,59],"Digital Twin","Precision Medicine","Precision Mental Health","Subclassification","Trajectories","Subtypes","Person-reported Outcomes (PRO)","Ecological Momentary Assessment (EMA)","Continuous Glucose Monitoring (CGM)","People with Diabetes (PWD)","Diabetes Mellitus","HbA1c","Depression","Anxiety","Eating disorder","2025-11-27",{"date":104,"type":45},"2025-12-04",{"date":106,"type":45},"2025-01-01",{"date":108,"type":21},"2027-12-31",{"name":110,"class":52},"Forschungsinstitut der Diabetes Akademie Mergentheim",3,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":120,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":53},"100596224","behavioral-therapy-and-glp-1-analogue-effects-on-binge-eating-weight-and-coping-in-obesity-100596224","NCT07042672","Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity","Behavioral Therapy With and Without GLP-1 Analogue in Patients With Morbid Obesity and Binge Eating Disorder: A Clinical Prospective Observational Study on Body Weight, Binge Eating Behavior, and Harmful Coping Strategies","BETTER-GLP1","Inclusion criteria\n\n1. Severe obesity defined as BMI \\>40 kg\u002Fm2 or 35 kg\u002Fm2 with obesity-related comorbidities: coronary artery disease, heart failure, hypertension, atrial fibrillation, cerebral stroke, venous thromboembolism, obstructive sleep apnea, obesity hypoventilation syndrome, type 2 diabetes mellitus, non-alcoholic fatty liver disease, dyslipidemia, osteoarthritis and polecystic ovary syndrome\n2. Age between 18 to 65 years\n3. Diagnosis of BED according to DSM-5 criteria\n4. Willingness to participate and provide informed consent\n5. Able to understand and communicate in Norwegian\n\nExclusion criteria\n\n1. Pregnant or lactating women, as well as women planning pregnancy within one year.\n2. Current use medications with major effects on appetite regulation or weight (including, but not limited to systemic glucocorticoids and antipsychotic medication)\n3. Renal failure with estimated glomerular filtration rate less than 30 mL\u002Fmin\u002F1,73m2\n4. Liver failure with either ASAT and\u002For ALAT 5 times upper reference limit, or ALP and\u002For GT more than 3 times upper reference limit, or clinical signs of liver decompensation\n5. Active cancer\n6. Previous medullary thyroid cancer\n7. Previous pancreatitis\n8. Active substance abuse (but previous drug abuse accepted)\n9. Medical or psychological treatment within the specialized health care service for eating disorders within the last 6 months.\n10. Ongoing severe psychiatric disease that makes them unable to follow the lifestyle treatment program\n11. Any illness or prior treatment that in the opinion of the investigator would jeopardize the patient's participation in the study or impact integrity and\u002For quality of study data.\n12. Previous bariatric surgery\n13. Use of appetite suppressing drugs (e.g., GLP-1 analogues and\u002For naltrexone\u002Fbupropion) within the last 6 months\n14. Participation in another clinical study involving an investigational medicinal product within 1 month prior to study inclusion",{"count":121,"type":21},80,"This study is a clinical, longitudinal, non-randomized, prospective observational study that seeks to compare the treatment effects and safety of using GLP-1 analogues versus not using appetite suppressants during a lifestyle treatment program that includes individual consultations every fourth month and 10 weeks of CBT-E group therapy in patients with both obesity and BED.\n\nThe primary objective of this study is to evaluate the impact on BED symptomatology, while the secondary objectives include examining the potential adoption of alternative harmful coping mechanisms. Additionally, the study will assess psychological well-being and weight changes and their consequent influence on obesity-associated comorbid conditions.\n\nAdult patients with coexisting obesity and BED presenting at the Obesity clinic at Haukeland University Hospital, Bergen, Norway, will be included Patients will be divided into two groups: Group-GLP1 (n = 40), who will use GLP-1 analogues, and Group-NoMED (n = 40), who will not use appetite suppressants. Both groups will otherwise follow the routine standardized patient care pathway with follow-up controls every four months and participation in CBT group therapy sessions.\n\nChanges in symptoms of BED, alternative harmful coping strategies and mental health will be recorded at baseline and 12 months using patient-reported questionnaires, as well as anthropometric and biochemical data.",[33,27,34,35,124,125,126],"GLP-1","CBT","Obesity &Amp; Overweight","2025-09-09",{"date":129,"type":45},"2025-09-15",{"date":131,"type":45},"2025-07-01",{"date":133,"type":21},"2028-12-31",{"name":135,"class":52},"Haukeland University Hospital",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":143,"maxAge":18,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":147,"conditions":148,"keywords":149,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":4},"100535504","conceptualisation-of-a-network-approach-to-complete-the-classification-of-eating-disorders-with-the-aim-of-better-personalising-their-management-100535504","NCT06252688","Conceptualisation of a Network Approach to Complete the Classification of Eating Disorders With the Aim of Better Personalising Their Management","CASCADE","Inclusion Criteria:\n\n* Patient with an eating disorder according to DSM-V criteria\n* Patient aged from 15 to 65 years\n* Patient who performs the day-hospital evaluation\n* Patient affiliated to a French social security system\n* Patient able to understand the nature, the aim and the methodology of the study\n* For minor one of the legal guardians gave his consent\n\nExclusion Criteria:\n\n* Patient in an unstable somatic state (eg severe metabolic disorder making impossible or unreliable neuropsychological assessments)\n* Patient's refusal to participate\n* Patient protected by law (guardianship or curatorship)\\*\n* Pregnant or nursing women. A dosage of βHCG will be performed to ensure the absence of pregnancy","15 Years",{"count":145,"type":21},840,[24],"Eating disorders (EDBs) are mental disorders with a great impact on the lives of individuals as well as a great cost imposed on society. The treatments currently available rely on different forms of psychotherapies with an unsatisfactory response rate as well as a considerable relapse rate . One of the reasons underlying the low success of available therapeutic modalities would be the heterogeneity of the clinical presentation of EDs, making their classification and the personalization of their treatment more difficult.The investigators hypothesize that a secondarily dimensional classification approach (respecting the categorical classification currently in use) of EDs based on the different dimensions disturbed in these disorders as well as in their comorbidities, would better represent their nosographic reality, which could provide patients with more personalized and potentially more effective care.",[35,34],[150,151,152,153,154,155],"Anorexia nervosa","Bulimia","Binge eating disorders","Neuropsychology","Neurocognitiond","Daily functioning","NOT_YET_RECRUITING","2024-02-08",{"date":159,"type":45},"2024-02-12",{"date":161,"type":21},"2024-02-15",{"date":163,"type":21},"2031-11-15",{"name":165,"class":52},"University Hospital, Montpellier"]